In 2023, the import volume of Cortisone, Hydrocortisone, Prednisone, and Prednisolone to China was approximately 930 kilograms. The forecasts from 2024 to 2028 indicate a steady increase in imports, starting at 968.53 kilograms in 2024 and culminating at 1150 kilograms in 2028. This reflects an annual average growth rate (CAGR) of approximately 4.37% over the five-year period. The year-on-year growth from 2024 to 2025 is anticipated to be about 4.3%, maintaining a consistent upward trajectory through the forecast period.
Future trends to watch for include potential regulatory changes in China’s pharmaceutical market, technological advancements in synthetic hormone production, and international trade agreements that may influence import volumes. Additionally, the growing prevalence of autoimmune diseases and endocrine disorders might further drive demand for these corticosteroids. Continuous monitoring of these factors will be crucial for adjusting forecasts and strategizing market entry or expansion.
